دورية أكاديمية
Fertility-sparing treatment and follow-up in patients with cervical cancer, ovarian cancer, and borderline ovarian tumours: guidelines from ESGO, ESHRE, and ESGE.
| العنوان: | Fertility-sparing treatment and follow-up in patients with cervical cancer, ovarian cancer, and borderline ovarian tumours: guidelines from ESGO, ESHRE, and ESGE. |
|---|---|
| المؤلفون: | Morice P; Department of Gynecological Surgery, Gustave Roussy Cancer Campus, Villejuif, France; Université Paris Saclay, Paris, France. Electronic address: philippe.morice@gustaveroussy.fr., Scambia G; Department of Women, Children, and Public Health Sciences, Fondazione Policlinico Universitario A Gemelli IRCCS, Rome, Italy., Abu-Rustum NR; Gynecologic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Acien M; Institute of Women's Health, University College London, London, UK; Grant Next Generation Department of Gynecology, Miguel Hernandez University, Alicante, Spain., Arena A; Division of Gynaecology and Human Reproduction Physiopathology, IRCCS, Azienda Ospedaliero-Univeristaria di Bologna, Bologna, Italy; Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy., Brucker S; Department of Obstetrics and Gynecology, University of Tübingen, Tübingen, Germany; Department of Women's Health, University Hospital Tübingen, Tübingen, Germany., Cheong Y; Human Development and Health, Faculty of Medicine, University of Southampton, Southampton, UK., Collinet P; Unité de Chirurgie Gynécologique, Hôpital Privé le Bois, Groupe Ramsay Lille Metropole, Lille, France., Fanfani F; Department of Women, Children, and Public Health Sciences, Fondazione Policlinico Universitario A Gemelli IRCCS, Rome, Italy., Filippi F; Infertility Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy., Eriksson AGZ; Department of Gynecologic Oncology, Division of Cancer Medicine, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway., Gouy S; Department of Gynecological Surgery, Gustave Roussy Cancer Campus, Villejuif, France; Université Paris Saclay, Paris, France., Harter P; Department of Gynaecology and Gynaecologic Oncology, Kliniken Essen Mitte, Essen, Germany., Matias-Guiu X; Department of Pathology, Hospital Universitari Arnau de Vilanova, Lleida, Spain., Pados G; Department of Obstetrics and Gynaecology, Papageorgiou General Hospital, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece., Pakiz M; Department for Gynaecologic and Breast Oncology, University Medical Center Maribor, Maribor, Slovenia., Querleu D; Division of Gynecologic Oncology, Fondazione Policlinico Universitario A Gemelli IRCCS, Rome, Italy., Rodolakis A; Unit of Gynaecologic Oncology, Alexandra Hospital, National and Kapodistrian University of Athens, Athens, Greece., Rousset-Jablonski C; Department of Surgery, Centre Léon Bérard, Lyon, France; Obstetrics and Gynecology, Hôpital Femme Mère Enfant, Bron, France., Stepanyan A; Gynecologic Oncology Service, Nairi Medical Center, Yerevan, Armenia., Testa AC; Department of Women, Children, and Public Health Sciences, Fondazione Policlinico Universitario A Gemelli IRCCS, Rome, Italy., Macklon KT; Fertility Clinic, Department of Gynecology, Fertility and Obstetrics Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Tsolakidis D; Department of Obstetrics and Gynaecology, Papageorgiou General Hospital, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece., De Vos M; Centre for Reproductive Medicine, University Hospital Brussels, Brussels, Belgium; Follicle Biology Laboratory, Vrije Universiteit Brussel, Brussels, Belgium., Planchamp F; Institut Bergonié, Bordeaux, France., Grynberg M; Université Paris Saclay, Paris, France; Department of Reproductive Medicine and Fertility Preservation, Hopital Antoine Béclère, Clamart, France; Department of Reproductive Medicine and Fertility Preservation, Hopital Jean Verdier, Bondy, France. |
| المصدر: | The Lancet. Oncology [Lancet Oncol] 2024 Aug 28. Date of Electronic Publication: 2024 Aug 28. |
| Publication Model: | Ahead of Print |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: London : Lancet Pub. Group, c2000- |
| مستخلص: | The European Society of Gynaecological Oncology, the European Society of Human Reproduction and Embryology, and the European Society for Gynaecological Endoscopy jointly developed clinically relevant and evidence-based guidelines focusing on key aspects of fertility-sparing strategies and follow-up of patients with cervical cancers, ovarian cancers, and borderline ovarian tumours. The developmental process of these guidelines is based on a systematic literature review and critical appraisal involving an international multidisciplinary development group consisting of 25 experts from relevant disciplines (ie, gynaecological oncology, oncofertility, reproductive surgery, endoscopy, imaging, conservative surgery, medical oncology, and histopathology). Before publication, the guidelines were reviewed by 121 independent international practitioners in cancer care delivery and patient representatives. The guidelines comprehensively cover oncological aspects of fertility-sparing strategies during the initial management, optimisation of fertility results and infertility management, and the patient's desire for future pregnancy and beyond. Competing Interests: Declaration of interests PM reports having had an advisory role or received speaker's honoraria (paid to him or to his institution) from GlaxoSmithKline, AstraZeneca, and ImmunoGen. GS reports grants or contracts from MSD, consulting fees from Tesaro Bio Italy and Johnson and Johnson, and payment or honoraria from Clovis Oncology Italy. NRA-R reports grants or contracts from Grail (paid to the institution). FFi reports honoraria from Theramex and Organon, and support for attending and travelling to meetings from Organon, Merck-Serono, and Theramex (paid to the institution). SB reports honoraria from MSD; support for attending and travelling to meetings from Hologic, MSD, and Pfizer; and honoraria for participation on a data safety monitoring board or advisory board from Hologic. CR-J reports payment for lectures (paid to the institution) from Organon and Novartis, speakers bureau (paid to the institution) from Gédéon Richter and Roche, and for manuscript writing (paid to the institution) from Roche. All other authors declare no competing interests. (Copyright © 2024 Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies. Published by Elsevier Ltd.. All rights reserved.) |
| تواريخ الأحداث: | Date Created: 20240831 Latest Revision: 20240831 |
| رمز التحديث: | 20240902 |
| DOI: | 10.1016/S1470-2045(24)00262-6 |
| PMID: | 39216500 |
| قاعدة البيانات: | MEDLINE |
Full Text via ClinicalKey 
Full Text Finder | تدمد: | 1474-5488 |
|---|---|
| DOI: | 10.1016/S1470-2045(24)00262-6 |